A new subgroup analysis from the Phase 3 PSMAddition trial shows that adding the radioligand therapy Pluvicto to standard hormone-based treatment significantly improves outcomes for patients with metastatic hormone-sensitive prostate cancer.
Researchers found that the treatment reduced the risk of disease progression on imaging by a similar amount across all patient groups, including those with high- or low-volume disease and those with newly diagnosed or recurrent cancer. The benefit closely matched the positive results seen in the overall trial population.
The combination therapy also delayed PSA progression and showed early signs of postponing the development of metastatic castration-resistant prostate cancer. Importantly, patients with low-volume disease did not experience higher toxicity despite receiving the full radioligand dose. Quality of life remained well maintained across all subgroups.
The findings support broader use of Pluvicto in metastatic hormone-sensitive prostate cancer. However, researchers noted that treatment decisions should still be individualized, particularly for patients with lower disease burden. Advanced PSMA PET imaging may help doctors better identify which patients are most likely to benefit from the therapy.